AUTHORS
Thomas Francis Fusillo, DO, MS, MHA, Ang Li, MD, MS2, Omid Jafari, Senior Software Engineering and Programming Associate3, Zihan Yang, MS4, Sarah E Sartain, MD5, Kavitha Ramaswamy6, Ofir Wolach, MD7, Mark Blaine Geyer, MD8, Jeffrey Zwicker, MD9, Avi Leader, MD10
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Baylor College of Medicine, Houston, Texas, United States
3 Baylor College of Medicine, Houston, Texas, United States
4 The University of Texas Health Science Center at Houston, Houston, Texas, United States
5 Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Background: The incidence of venous thromboembolism (VTE) in patients with acute lymphoblastic leukemia (ALL) treated with asparaginase-based regimens is high. Pegaspargase (PEG) and the newer longer acting calaspargase pegol (CAL) have largely replaced L-asparaginase in the U.S. We aimed to evaluate incidence and risk factors of VTE in patients with ALL receiving PEG- or CAL-based regimens.
Methods: This is a retrospective multicenter cohort study using Epic Cosmos, a collaborative dataset of Epic health systems including more than 300 million patients from all 50 states, D.C., and non-U.S. sites (cosmos.epic.com). The current study included patients of all ages in the U.S. with a diagnosis of ALL (C91.0x) who received either CAL or PEG from 2018-2024. Patients were indexed on the day of the first CAL/PEG administration. Exclusions included baseline therapeutic anticoagulation on/before index, acute VTE in the last month, and prior receipt of asparaginase. Baseline enoxaparin prophylaxis (PPX) was defined using a -2 to +1-day window from index.
Patient demographics, laboratory values, medications, and vitals were extracted on index date using previous protocols (PMID: 41796432). VTE was defined using previously validated ICD-10 diagnosis codes, and the diagnosis dates were anchored by the POA flag and CPT codes. The cumulative incidence of VTE (and 95% confidence interval [CI]) was estimated with death as a competing risk. From a list of a priori chosen risk factors, we built a multivariable Fine-Gray regression model to evaluate VTE risk factors with right censoring at 90 days. Subdistribution hazard ratio (SHR) and 95% CI were reported. Mortality was assessed by the Kaplan Meier method.
Results: Among 11,414 patients from 161 health systems in the final cohort, the median age was 8 (IQR 4-16), 42% were female, and 27% were Hispanic. Self-reported race included 60% White, 10% Black, and 6% Asian. There were 6,259 (55%) aged 1-9.9 years, 2,804 (25%) 10-17.9, 597 (5%) 18-20.9, 1,383 (12%) 21-44.9, and 371 (3%) 45+ years. CAL was given to 3,038 (27%) patients (99% <21 years); PEG was given in 8,376 (73%) patients (80% <21 years). Among 9,388 patients (82%) who received CAL/PEG inpatient, the median time from admission to CAL/PEG administration was 6 days (IQR 5-7). Only 3% received enoxaparin PPX, though this increased to 13% in 21-44.9 years and 18% in 45+ years.
The 30- and 90-day incidence of VTE (95% CI) was 3.3% (3.0-3.6) and 5.6% (5.2-6.1), respectively. The age-specific 90-day incidences were 2.4% (2.1-2.8) for 1-9.9 years, 7.0% (6.1-8.0) for 10-17.9 years, 11.4% (9.0-14.1) for 18-20.9 years, 13.0% (11.3-14.9) for 21-44.9 years, and 12.5% (9.3-16.2) for 45+ years. Among patients <21 years, the 90-day incidence was 4.9% (4.1-5.7) for CAL and 4.1% (3.6-4.6) for PEG. At 90 days, there were 375 upper-extremity deep vein thromboses (DVT), 227 lower-extremity DVT, and 48 cerebral venous sinus thromboses (CVST), non-exclusively. Mortality was 1.6% at 90 days, ranging from 0.8% in the youngest to 9.1% in the oldest subgroups.
In multivariable analysis, increasing age was the strongest risk factor for VTE. Compared with 1-9.9 years, SHRs (95% CIs) were 3.00 (2.41-3.74) for 10-17.9, 5.12 (3.80-6.90) for 18-20.9, 5.83 (4.56-7.46) for 21-44.9, and 5.15 (3.59-7.37) for 45+ years. Additional VTE risk factors included prior VTE (SHR 2.68; 1.73-4.16), inpatient asparaginase administration (SHR 2.17; 1.68-2.80), non-type O blood (SHR 1.46; 1.22-1.76), and obesity (SHR 1.47; 1.23-1.75). Asian race (SHR 0.58; 0.37-0.91), Hispanic ethnicity (SHR 0.82; 0.67-0.99), and platelet <50,000/µL (SHR 0.75; 0.63-0.89) were associated with lower VTE risk, whereas receipt of PEG (vs CAL; SHR 0.84; 0.69-1.02) and hemoglobin <10 g/dL (SHR 0.87; 0.72-1.05) trended toward lower VTE risk. Prophylactic enoxaparin (SHR 1.22; 0.90-1.66) did not have significant association.
Conclusions: In this large multicenter cohort of patients with ALL treated with PEG- and CAL-based regimens, we demonstrate distinct VTE risk profiles in different age groups. Pediatric patients have a lower incidence of VTE than those aged 18+, while the incidence among adults was similar across age sub-groups. Consistent with the ASH guidelines, enoxaparin PPX is not routinely used. There are unique clinical factors that additionally modify VTE risks. The numerically higher VTE incidence observed in patients under the age of 21 receiving CAL compared to PEG warrants further research.
DISCLOSURES
Thomas Francis Fusillo, DO, MS, MHA: Syndax Pharmaceuticals - Current equity holder in publicly-traded company; Revolution Medicines - Current equity holder in publicly-traded company